Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years
dc.contributor.author | Hawton, A | |
dc.contributor.author | Goodwin, E | |
dc.contributor.author | Boddy, K | |
dc.contributor.author | Freeman, Jennifer | |
dc.contributor.author | Thomas, S | |
dc.contributor.author | Chataway, J | |
dc.contributor.author | Green, C | |
dc.date.accessioned | 2020-09-15T07:41:36Z | |
dc.date.available | 2020-09-15T07:41:36Z | |
dc.date.issued | 2020-09-03 | |
dc.identifier.issn | 1352-4585 | |
dc.identifier.issn | 1477-0970 | |
dc.identifier.other | ARTN 1352458520954172 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/16259 | |
dc.description.abstract |
<jats:sec><jats:title>Background:</jats:title><jats:p> It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effects in cost-effectiveness analyses and in 2012, in the United Kingdom, the National Institute for Health and Care Excellence called for an improvement in the cost-effectiveness framework for assessing MS treatments. </jats:p></jats:sec><jats:sec><jats:title>Objective and Methods:</jats:title><jats:p> This review describes what is meant by cost-effectiveness in health/social care funding decision-making, and usual practice for assessing treatment benefits. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We detail the use of the quality-adjusted life-year (QALY) in resource allocation decisions, and set out limitations of this approach in the context of MS. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> We conclude by highlighting methodological and policy developments which should aid addressing these limitations. </jats:p></jats:sec> | |
dc.format.extent | 135245852095417-135245852095417 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | SAGE Publications | |
dc.subject | Multiple sclerosis | |
dc.subject | cost-effectiveness | |
dc.subject | quality-adjusted life-years | |
dc.subject | cost-effectiveness analysis | |
dc.subject | health-related quality of life | |
dc.subject | quality of life | |
dc.title | Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Research Support, Non-U.S. Gov't | |
dc.type | Review | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000566168400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 3 | |
plymouth.volume | 28 | |
plymouth.publication-status | Published | |
plymouth.journal | Multiple Sclerosis Journal | |
dc.identifier.doi | 10.1177/1352458520954172 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Health Professions | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Health and Community | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2020-06-18 | |
dc.rights.embargodate | 2020-9-18 | |
dc.identifier.eissn | 1477-0970 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1177/1352458520954172 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-09-03 | |
rioxxterms.type | Journal Article/Review |